Advanced Methylation Detection Technology

Next-generation liquid biopsy driven by genomics and machine learning

Exclusively licensed by the
University of Southern California
‍

Our Proprietary Platform

Harnessing advanced genomic science and AI to deliver clarity in cancer diagnosis
— detecting cancer when it’s present and confidently ruling it out when it’s not.

Methylation Signal Capture

Our platform translates DNA methylation changes into measurable patterns, enabling precise identification of cancer-specific signals.

Next-Generation Sequencing

Profiles thousands of CpG sites across the genome in a single test. Why it matters: Detects cancer signals in blood with exceptional accuracy.

AI-powered Analysis

Machine learning trained on extensive clinical datasets. Why it matters: Integrates complex methylation patterns into a single clear diagnostic result

Technical Advantages

Superior Specificity

Our methylation-based approach consistently achieves >97% specificity, compared to a maximum of ~72% with other biomarkers. This means fewer false positives, fewer unnecessary surgeries, and greater clinical confidence

Comprehensive Genomic Coverage

By analyzing multiple genomic regions simultaneously, our test generates a robust cancer signature — overcoming tumor heterogeneity and maintaining performance across different ovarian cancer subtypes.

Liquid Biopsy

Reliable Results

Liquid Biopsy Innovation

Bodour Salhia, PhD

OvaPrint™ is our first liquid biopsy test, designed to accurately distinguish malignant from benign adnexal masses — a critical unmet need in women’s health.

Originating from pioneering research in Dr. Bodour Salhia’s laboratory, OvaPrint is built on more than a decade of rigorous epigenomics research. Dr. Salhia’s team was among the first to demonstrate the power of cell-free DNA methylation in blood (PMID: 26380585).

This foundational work, now translated by CpG Diagnostics, helped demonstrate the potential of methylation profiling as a powerful approach to cancer diagnostics.

Our Evidence is Growing

Our pivotal study, published in Clinical Cancer Research (2023), demonstrated that OvaPrint™ distinguishes high-grade serous ovarian carcinoma (HGSOC) - the most lethal ovarian cancer subtype - from benign adnexal masses with unprecedented specificity and sensitivity. Building on this foundation, OvaPrint™ has since been expanded to include other epithelial ovarian cancer subtypes.

This proof-of-concept laid the groundwork for our national clinical trial now underway, designed to rigorously validate OvaPrint across diverse ovarian cancer subtypes, patient populations, and clinical settings.

Learn More About OvaPrint

AACR

2023

Papers and Publications